These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

328 related articles for article (PubMed ID: 25586682)

  • 1. Use of boosted protease inhibitors reduces Kaposi sarcoma incidence among male veterans with HIV infection.
    Kowalkowski MA; Kramer JR; Richardson PR; Suteria I; Chiao EY
    Clin Infect Dis; 2015 May; 60(9):1405-14. PubMed ID: 25586682
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical characteristics, predictors of immune reconstitution inflammatory syndrome and long-term prognosis in patients with Kaposi sarcoma.
    Volkow P; Cesarman-Maus G; Garciadiego-Fossas P; Rojas-Marin E; Cornejo-Juárez P
    AIDS Res Ther; 2017 May; 14(1):30. PubMed ID: 28558783
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Changing Incidence and Risk Factors for Kaposi Sarcoma by Time Since Starting Antiretroviral Therapy: Collaborative Analysis of 21 European Cohort Studies.
    Cancer Project Working Group for the Collaboration of Observational HIV Epidemiological Research Europe (COHERE) study in EuroCoord
    Clin Infect Dis; 2016 Nov; 63(10):1373-1379. PubMed ID: 27535953
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The changing pattern of Kaposi sarcoma in patients with HIV, 1994-2003: the EuroSIDA Study.
    Mocroft A; Kirk O; Clumeck N; Gargalianos-Kakolyris P; Trocha H; Chentsova N; Antunes F; Stellbrink HJ; Phillips AN; Lundgren JD
    Cancer; 2004 Jun; 100(12):2644-54. PubMed ID: 15197808
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Differential impact of combination antiretroviral therapy in preventing Kaposi's sarcoma with and without visceral involvement.
    Grabar S; Abraham B; Mahamat A; Del Giudice P; Rosenthal E; Costagliola D
    J Clin Oncol; 2006 Jul; 24(21):3408-14. PubMed ID: 16849755
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Predictors of immune reconstitution inflammatory syndrome-associated with kaposi sarcoma in mozambique: a prospective study.
    Letang E; Almeida JM; Miró JM; Ayala E; White IE; Carrilho C; Bastos R; Nhampossa T; Menéndez C; Campbell TB; Alonso PL; Naniche D
    J Acquir Immune Defic Syndr; 2010 Apr; 53(5):589-97. PubMed ID: 19801945
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immune reconstitution inflammatory syndrome associated with Kaposi sarcoma: higher incidence and mortality in Africa than in the UK.
    Letang E; Lewis JJ; Bower M; Mosam A; Borok M; Campbell TB; Naniche D; Newsom-Davis T; Shaik F; Fiorillo S; Miro JM; Schellenberg D; Easterbrook PJ
    AIDS; 2013 Jun; 27(10):1603-13. PubMed ID: 23462220
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Kaposi Sarcoma Risk in HIV-Infected Children and Adolescents on Combination Antiretroviral Therapy From Sub-Saharan Africa, Europe, and Asia.
    ; Rohner E; Schmidlin K; Zwahlen M; Chakraborty R; Clifford G; Obel N; Grabar S; Verbon A; Noguera-Julian A; Collins IJ; Rojo P; Brockmeyer N; Campbell M; Chêne G; Prozesky H; Eley B; Stefan DC; Davidson A; Chimbetete C; Sawry S; Davies MA; Kariminia A; Vibol U; Sohn A; Egger M; Bohlius J
    Clin Infect Dis; 2016 Nov; 63(9):1245-1253. PubMed ID: 27578823
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of protease inhibitor-based highly active antiretroviral therapy on survival in HIV-associated advanced Kaposi's sarcoma patients treated with chemotherapy.
    Leitch H; Trudeau M; Routy JP
    HIV Clin Trials; 2003; 4(2):107-14. PubMed ID: 12671778
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Longer duration of combination antiretroviral therapy reduces the risk of Hodgkin lymphoma: A cohort study of HIV-infected male veterans.
    Kowalkowski MA; Mims MA; Day RS; Du XL; Chan W; Chiao EY
    Cancer Epidemiol; 2014 Aug; 38(4):386-92. PubMed ID: 24947588
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of immune reconstitution on the incidence of HIV-related Hodgkin lymphoma.
    Kowalkowski MA; Mims MP; Amiran ES; Lulla P; Chiao EY
    PLoS One; 2013; 8(10):e77409. PubMed ID: 24098586
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical outcomes of HIV-infected patients with Kaposi's sarcoma receiving nonnucleoside reverse transcriptase inhibitor-based antiretroviral therapy in Uganda.
    Asiimwe F; Moore D; Were W; Nakityo R; Campbell J; Barasa A; Mermin J; Kaharuza F
    HIV Med; 2012 Mar; 13(3):166-71. PubMed ID: 22112164
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Risk of Kaposi sarcoma during the first months on combination antiretroviral therapy.
    Lacombe JM; Boue F; Grabar S; Viget N; Gazaignes S; Lascaux-Cametz AS; Pacanowski J; Partisani M; Launay O; Matheron S; Rosenthal E; Rouveix E; Tattevin P; de Truchis P; Costagliola D; Goedert JJ
    AIDS; 2013 Feb; 27(4):635-43. PubMed ID: 23196937
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Human immunodeficiency virus-associated Kaposi sarcoma as an immune reconstitution inflammatory syndrome: a literature review and case report.
    Feller L; Anagnostopoulos C; Wood NH; Bouckaert M; Raubenheimer EJ; Lemmer J
    J Periodontol; 2008 Feb; 79(2):362-8. PubMed ID: 18251652
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of single and boosted protease inhibitor versus nonnucleoside reverse transcriptase inhibitor-containing cART regimens in antiretroviral-naïve patients starting cART after January 1, 2000.
    Mocroft ; Horban ; Clumeck ; Stellbrink ; Monforte dA; Zilmer ; Kirk ; Gatell ; Phillips ; Lundgren ;
    HIV Clin Trials; 2006; 7(6):271-84. PubMed ID: 17208897
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Remission from Kaposi's sarcoma on HAART is associated with suppression of HIV replication and is independent of protease inhibitor therapy.
    Martinez V; Caumes E; Gambotti L; Ittah H; Morini JP; Deleuze J; Gorin I; Katlama C; Bricaire F; Dupin N
    Br J Cancer; 2006 Apr; 94(7):1000-6. PubMed ID: 16570046
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cancer risk in the Swiss HIV Cohort Study: associations with immunodeficiency, smoking, and highly active antiretroviral therapy.
    Clifford GM; Polesel J; Rickenbach M; Dal Maso L; Keiser O; Kofler A; Rapiti E; Levi F; Jundt G; Fisch T; Bordoni A; De Weck D; Franceschi S;
    J Natl Cancer Inst; 2005 Mar; 97(6):425-32. PubMed ID: 15770006
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A comparison of regimens based on non-nucleoside reverse transcriptase inhibitors or protease inhibitors in preventing Kaposi's sarcoma.
    Portsmouth S; Stebbing J; Gill J; Mandalia S; Bower M; Nelson M; Bower M; Gazzard B
    AIDS; 2003 Jul; 17(11):F17-22. PubMed ID: 12853764
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immune reconstitution and risk of Kaposi sarcoma and non-Hodgkin lymphoma in HIV-infected adults.
    Jaffe HW; De Stavola BL; Carpenter LM; Porter K; Cox DR;
    AIDS; 2011 Jul; 25(11):1395-403. PubMed ID: 21572307
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of PI and NNRTI HAART-based therapy on oral lesions of Brazilian HIV-infected patients.
    Ortega KL; Vale DA; Magalhães MH
    J Oral Pathol Med; 2009 Jul; 38(6):489-94. PubMed ID: 19453845
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.